Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT® , a biosimilar referencing Herceptin® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT® is the first trastuzumab biosimilar to receive regulatory approval in Europe.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/
The EC approval of ONTRUZANT® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT® will be commercialized by MSD, which is known as Merck in the United States and Canada.
“Breast cancer remains the most common form of cancer affecting women. We hope ONTRUZANT will play an important role expanding patient access to trastuzumab across the region,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry's strongest biosimilar pipelines, so that more cancer patients and healthcare systems across Europe will benefit from biosimilars.”
ONTRUZANT® is the fourth biosimilar developed by Samsung Bioepis to receive EC marketing authorization. Samsung Bioepis has also received marketing authorizations for Benepali® (etanercept), Flixabi® (infliximab) and Imraldi® (adalimumab).
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six first-wave candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
i Herceptin ® is a registered trademark of Genentech Inc.
Samsung Bioepis Co., Ltd.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
JPMORGAN-CHASE17.7.2018 21:42 | pressemeddelelse
JPMorgan Chase Bank announces the placement of cash-settled exchangeable bonds into Ping An Insurance (Group) Company of China Limited due 2020
MA-BOSTON-CAPITAL17.7.2018 16:02 | pressemeddelelse
Boston Capital Announces Closing of Boston Capital Income & Value U.S. Apartment Fund
CA-AMOBEE17.7.2018 15:15 | pressemeddelelse
Amobee Wins Auction Process to Acquire Videology Assets
JPMORGAN-CHASE17.7.2018 14:02 | pressemeddelelse
JPMorgan Chase Bank launches offering of cash-settled exchangeable bonds into Ping An Insurance (Group) Company of China Limited due 2020
NC-LENOVO17.7.2018 14:02 | pressemeddelelse
Lenovo Leaps Forward with Next-Generation ThinkAgile Composable Cloud Platform
PA-GREENE-TWEED17.7.2018 13:03 | pressemeddelelse
Greene Tweed Achieves Nadcap Accreditation for Non-Metallic Materials Testing
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum